While the latest cancer drugs emerging from drug and biotechnology company labs can come with hefty price tags, they don't necessarily have a lot of evidence showing they actually work.
President Obama's upcoming visit to Hiroshima in pursuit of a nuclear weapon-free world will unleash uncomfortable emotions on both sides of the Pacific. He ought to note what survivors of the blast taught mankind about the long-term effects of radiation exposure and the threat posed by nuclear war.
In most presidential election years, the politics of healthcare at least has a nodding acquaintance with reality. This year, the two aren't even on speaking terms.
It was a field day last week for health wonks in Washington. The CMS issued two major rules—one final, one proposed—that will shape how nearly half the nation's healthcare tab gets spent over the next decade.
New CDC data show white women on average lived slightly shorter lives in 2014 compared to 2013. Most experts agreed it was a worrisome harbinger of what awaits other groups suffering the ill-effects of our increasingly unequal society.
The skeptics were out in force last week when the CMS launched a major expansion of its comprehensive primary-care initiative. They are way off base.
State Medicaid agencies have launched a wide array of payment and care-delivery reforms, some of which go further than the federal government's efforts. While they offer the promise of delivering higher-quality care, it's unreasonable to expect them to deliver lower costs, at least in the short run.
Ever heard of the “therapeutic illusion”? I hadn't until I read a Perspective article in last week's New England Journal of Medicine that should be required reading for any healthcare executive serious about moving his or her organization from volume-driven to value-based care.
Need a job? In most American towns and cities, the best place to find new employment opportunities is in healthcare. But healthcare isn't an economic savior.
Two recent patient-safety initiatives—one designed to curb opioid overprescribing and the other a heart-device recall—reveal the limits of voluntary action when it comes to avoiding harm from drugs and medical devices.
Everyone is in favor of value-based reimbursement in healthcare, right? If you're still wearing those rose-colored glasses, take a closer look at last week's reaction to Medicare's proposal to test new ways of paying for drugs administered in physician offices and hospital outpatient departments.
Texas' legislative effort to restrict abortion providers, to be reviewed this week by the U.S. Supreme Court in Whole Woman's Health v. Hellerstedt, has troubling economic implications for healthcare providers that go well beyond abortion. It's worth reviewing some of the issues raised by the case.